Avacta shares jump on partnership expansion with LG
, on Wednesday announced the expansion of its collaboration with LG Chem Life Sciences, part of the South Korean multinational conglomerate LG Group.
LG Chem has expanded its collaboration by nominating the second and third drug targets, for which has the potential for more milestone payments, Avacta said.
The milestone payments are part of Avacta’s Affimer® therapeutics development partnership and license agreement to develop Affimer® therapeutics in several disease areas.
In addition to development milestone payments, Avacta is entitled to royalties on any future product sales as per its agreement made in December 2018.
Shares in Avacta rose 10.73% to 19.6p during Wednesday morning trading
Alastair Smith, Chief Executive Officer, commented: "I am very pleased with the excellent progress made in the first programme with LG Chem.”
“Not only is this an important validation of the Affimer platform, confirming that it can be used to quickly generate potential candidate drug molecules for development, but it also means that we have taken an important step towards receiving the next substantial milestone payment under our collaboration agreement.”
He added: “Our partnership with LG Chem goes from strength to strength with their decision to nominate the next two drug targets.”
Follow News & Updates from Avacta Group here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.